Can I read Onvansertib and Paclitaxel Combined in Platinum-resistant Ovarian Carcinomas on EtoBox?

Onvansertib and Paclitaxel Combined in Platinum-resistant Ovarian Carcinomas by Roberta Affatato; Michela Chiappa; Federica Guffanti; Francesca Ricci; Laura Formenti; Robert Fruscio; Marta Jaconi; Maya Ridinger; Mark Erlander; Giovanna Damia is a Medicine article available to read on EtoBox.

What is Onvansertib and Paclitaxel Combined in Platinum-resistant Ovarian Carcinomas about?

## Background: Ovarian carcinoma is extremely sensitive to (platinum-based) chemotherapy; however, most patients will relapse with platinum-resistant disease, badly affecting their prognosis. Effective therapies for relapsing resistant tumors are urgently needed. ## Methods: We used patient-derived xenografts (PDXs) of ovarian carcinoma resistant to cisplatin (DDP) to test __in vivo__ the combination of paclitaxel (15 mg/kg i.v. once a week for 3 weeks) and onvansertib, a plk1 inhibitor, (50 mg/kg orally 4 days a week for 3 weeks). The PDX models were subcutaneously (s.c.) or orthotopically transplanted in nude mice and antitumor efficacy was evaluated as tumor growth inhibition and survival advantages of the combination over untreated and single agent treatment. ## Results: The combination of onvansertib and paclitaxel was very well tolerated with weight loss no greater than 15% in the combination group compared with the control group. In the orthotopically transplanted PDXs, single onvansertib and paclitaxel treatments prolonged survival; however, the combined treatment was much more active, with median survival from three- to six-fold times that of untreated mice. Findings were

Who reads Onvansertib and Paclitaxel Combined in Platinum-resistant Ovarian Carcinomas?

Author

Roberta Affatato; Michela Chiappa; Federica Guffanti; Francesca Ricci; Laura Formenti; Robert Fruscio; Marta Jaconi; Maya Ridinger; Mark Erlander; Giovanna Damia

Publisher

SAGE Publications

Published

2022

Language

EN

Field

Medicine (Health Sciences)